Chapter 18: Practical Applications of Immunology

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Have you ever stopped to really think about the invisible war our bodies are fighting, like every single day?

It's constant, isn't it?

Microbes everywhere.

Exactly.

And yet, most of the time, we just, well, we carry on.

How does that work?

Right.

And, maybe even more amazing, how have we learned to actually use our body's own defenses for these incredible medical breakthroughs?

That's the core of it, really.

Welcome to the Deep Dive.

Today, we're really getting into the practical side of immunology, pulling out the key stuff from a pretty comprehensive microbiology text.

Our mission, basically, is to break down the science.

You know, vaccines,

diagnostic tests,

make it all clear, give you some real insights, hopefully some aha moments, too.

Absolutely.

We want to look at the what and the why of these applications.

So we'll touch on history, the breakthroughs, but also the cutting edge tech, and always thinking about how it matters, you know, clinically or even environmentally.

Okay, let's kick things off with vaccines.

The power of prevention.

It's a quest that goes back way further than you might think.

Long before modern medicine, yeah.

Think about this.

1400s.

China.

Physicians were doing something called variolation.

Seems intense.

It does.

They'd have people, often kids,

inhale dried smallpox scabs.

The idea was to cause a mild case, leading to immunity.

And surprisingly often, it worked.

And that practice spread, didn't it, through Asia, North Africa, eventually Eurasia?

Right.

It took until 1717 for it to really hit Europe, thanks mainly to Lady Mary Monacue.

She saw it in Turkey, brought the idea back to England.

Still risky though.

Variolation had maybe a 1 % death rate, which sounds bad, but...

Compared to smallpox itself, which killed maybe 50%, it was a huge improvement, relatively speaking.

A calculated risk for sure.

Then comes the big leap, 1798, Edward Jenner.

Ah, Jenner.

The cowpox connection.

Exactly.

He noticed milkmaids who got cowpox, which is pretty mild in humans, didn't get smallpox.

So he thought maybe intentionally giving someone cowpox could protect them.

He did it.

Inoculated people with cowpox material.

And it worked.

It was safer than variolation and quickly became the standard.

And Louis Pasteur, later on, actually coined the term vaccination for it.

From Vaca, the Latin for cow, to honor Jenner.

So what's the science?

Why did cowpox work against smallpox?

Well, we now know the viruses are related.

Cowpox isn't serious for us, but injecting it triggers what we call a primary immune response.

Your body makes antibodies,

and crucially, it creates long -term memory cells.

Ah, the memory cells.

Right.

So if you're later exposed to the real smallpox virus, those memory cells jump into action.

You get a really fast, strong secondary immune response that just shuts down the infection before it starts.

It's like training your immune system.

And the results of this idea, and modern vaccines,

well, they're just incredible.

Transformative, smallpox, completely gone, globally eradicated.

And not just human diseases, rinderpest.

A viral disease in livestock, also eradicated.

And now, measles, polio, other big ones, are targeted for elimination worldwide.

It relies on this idea of herd immunity, right?

Exactly.

If enough people in a community are immune, usually through vaccination, the disease just can't spread easily.

Outbreaks become small, sporadic.

So it protects people who can't get vaccinated, like babies or people with weak immune systems.

Precisely.

They're sheltered by the immunity of the herd around them.

And you have to remember, for a lot of viruses, vaccination is pretty much the only tool we have.

There just aren't many good antiviral drugs out there.

So vaccines are our main weapon against many viruses.

They really are.

But making them isn't always straightforward, is it?

There are still challenges.

Oh, definitely.

Identifying the right antigens, the bits that trigger the best immune response, that's Understanding the microbes' life cycle, finding good animal models for testing,

and, you know, getting the funding.

Right.

It's why we still don't have really effective widespread vaccines for things like,

say, chlamydia or many fungi, protozoa, even parasitic worms.

They're just complex targets.

Very tricky.

OK, so how are these vaccines made?

Let's get into the different types.

It's like different training programs for the immune system.

Good analogy.

First up, you've got live attenuated vaccines.

Attenuated means weakened.

Exactly.

Living pathogens, but weakened so they don't cause serious disease.

They're great because they mimic a real infection very closely.

They actually replicate a bit in your body.

And that triggers a strong response.

A very strong one.

Both cellular and humoral immunity.

Often gives you lifelong protection.

Think MMR, measles, mumps, rubella, or the chickenpox vaccine.

But there's a slight risk.

A small one, yeah.

Because they're alive, there's a tiny chance they could mutate back to a more dangerous form.

It's rare, but it's why they're generally not given to people with severely weakened immune systems.

OK, so what's the alternative?

Well, you have inactivated, killed vaccines.

Here you take the whole microbe, but you kill it, usually with chemicals like formalin.

So it can't replicate at all?

Nope.

No replication.

But the dead microbe is still intact enough for the immune system to recognize it and learn from it.

Safer, then.

Generally considered safer, yes.

But the downside is the immune response isn't usually as strong or long -lasting as with live vaccines.

You typically need booster shots.

OK, example?

Rabies vaccine, the injectable flu shot, the Salk polio vaccine.

Those are inactivated.

Got it.

What else?

Then we get more targeted with subunit vaccines.

Instead of the whole microbe, alive or dead, you just use specific pieces, the antigenic fragments that trigger the best immune response.

You avoid using the whole cathogen.

Right.

You get the immune stimulation without the risks of the whole organism.

And there are different kinds of subunit vaccines.

Like what?

Combinant vaccines.

Here you use genetic engineering.

You take a harmless microbe, like yeast, and tweak its genes so it produces the antigen you want.

Clever.

Yeah.

The hepatitis B vaccine is a classic example, yeast producing a viral coat protein.

OK.

What other subunits?

Toxoid vaccines.

These target toxins produced by bacteria.

You take the toxin, inactivate it, making it a toxoid, and inject that.

Your body makes antibodies against the toxin.

Like tetanus, diphtheria.

Exactly.

Tetanus, diphtheria, also the cellular part of the pertussis vaccine.

These usually need boosters, maybe every 10 years or so.

And virus -like particles.

VLPs.

Ah, yes.

VLPs look like the structure of a virus, but they're empty shells.

No genetic material inside.

So totally non -infectious, but they look like the real thing to the immune system.

The HPV vaccine uses this, right?

That's a key example, yes.

Made using modified yeast, again.

OK.

You also mentioned polysaccharide vaccines.

Right.

These are based on the sugars, the polysaccharides, found in the outer capsule of some bacteria.

Like for Neisseria meningitidis or pneumococcal pneumonia.

But they have limitations.

Yeah.

They don't work very well in young children, say under two years old.

Their immune systems don't respond strongly to these types of antigens alone.

Which leads to conjugated vaccines.

Precisely.

To overcome that problem, you take the polysaccharide and chemically link it, or conjugate it, to a protein, often something like diphtheria or tetanus toxoid.

And that helps the kids' immune systems.

It helps immensely.

It recruits T cells into the response, creating a much stronger, longer -lasting immunity, even in infants.

The Hib vaccine hemophilus influenza type B was a major breakthrough using this approach.

OK.

Now for the really cutting -edge stuff.

Nucleic acid vaccines.

DNA vaccines.

Yes.

This is very exciting.

You inject actual DNA, either naked or maybe wrapped in a lipid coat that contains the genetic instructions for making a specific antigen.

So my cells make the antigen.

Your own cells become temporary vaccine factories.

They take up the DNA, produce the foreign protein, and present it to your immune system.

Wow.

And the immune response.

It's really good.

It seems to trigger both humoral and cellular immunity effectively, and generates good immunological memory.

Lots of potential here.

Trials are ongoing for Zika, HIV, influenza, and the Ebola vaccine, RVSV -Z -BOVAI, which uses a related vector approach, has shown amazing effectiveness.

And these vaccines sometimes need a little help.

Ajuvans.

Right.

Ajuvans.

Think of them as immune boosters added to the vaccine, things like alum or newer ones like MPL.

We don't always know the exact mechanism, but they definitely enhance the immune response, often by stimulating the innate immune system, the body's first responders.

Sort of like sounding the alarm.

That's a good way to put it.

They help ensure the adaptive immune system really pays attention.

And how we make these vaccines has changed, too, right?

Not always in eggs or animals.

Not anymore, for many.

Recombinant and DNA vaccines don't need a live host organism to grow the microbe.

That avoids issues like egg allergies for flu vaccines, or the difficulty of growing some viruses in cell culture.

It's cleaner, potentially faster.

This also seems to be opening up new ways to deliver vaccines.

Not just needles.

Definitely.

There's a lot of research into oral vaccines, easier to administer, no needles, potentially better for pathogens that enter through the gut.

We have oral polio and rotavirus vaccines already.

What else?

Skin patches.

Like the nanopatch, it delivers a dry vaccine formula right into the skin, targeting key immune cells there.

A huge advantage is that it might not need refrigeration.

That's massive for getting vaccines to remote areas.

A potential game changer for global health, yeah.

They're testing it for flu, polio, even things like tick -borne diseases.

And combining vaccines?

Combination vaccines are crucial, especially for infants who need protection against multiple diseases.

Putting several antigens into one shot, like DTaP -IPV -Hib, reduces the number of injections needed.

Makes sense.

So where is vaccine research headed next?

Well, the big targets remain things like AIDS, malaria, but researchers are also exploring vaccines for type 1 diabetes, maybe even drug addiction, Alzheimer's, cancer, allergies.

Cancer vaccines, really?

Liriputic ones, yeah.

Trying to train the immune system to target cancer cells.

But a major hurdle for many diseases is antigenic variability, flu changes every year, HIV changes constantly.

So the target keeps moving.

Exactly, which has led to new approaches like reverse vaccinology, using computers to scan entire mitrobial genomes to find potential vaccine candidates that might be more stable.

Which brings us, inevitably, to the topic of vaccine safety.

It's contentious sometimes.

It is.

And it's important to be clear, no vaccine, like no medicine, is 100 % safe or 100 % effective.

There can be side effects.

Usually mild.

Mostly mild, yes.

Sore arm, maybe a slight fever, headache, fatigue.

It varies by vaccine.

But severe reactions are very rare.

Let's think about that clinical case again.

The doctor getting pertussis from an unvaccinated baby and spreading it.

That scenario highlights the dilemma.

People who saw diseases like polio -paralyzed children or measles -caused serious complications understood the benefit versus the risk.

But parents today haven't seen those diseases, mostly thanks to vaccines.

Right.

So for them, the very small risk of a vaccine side effect can feel more immediate or worrying than the disease risk, which seems abstract.

And misinformation plays a huge role here.

A damaging role.

The supposed link between the MMR vaccine and autism, for instance, it was based on fraudulent research, completely debunked, the paper retracted.

But the fear lingers.

It persists.

False information spreads so easily, especially online.

And the consequence, we're seeing outbreaks of measles, mumps, pertussis diseases we thought we had under control returning in developed countries.

It's tragic.

There was also concern about thimerosal.

Yes, a mercury -based preservative.

As a precaution, it was removed or reduced in most childhood vaccines years ago, back Even though major studies didn't find evidence of harm from it in vaccines.

The overall impact of vaccines, though, is just staggering when you look at the numbers.

It really is diphtheria.

Thousands of deaths early last century, now virtually none in places like the U .S.

Rubella.

A massive epidemic in the 60s, now just a handful of cases.

Null blocks.

Killed hundreds of millions, now gone.

Polio.

Thousands paralyzed each year in the U .S.

in the 50s, eliminated from the Americas.

The evidence is overwhelming.

Vaccines are one of public health's greatest triumphs.

So why do these diseases still exist anywhere?

Several reasons.

Poverty and lack of infrastructure in some parts of the world make widespread vaccination difficult.

Sometimes immunity wanes over time, like with pertussis, requiring boosters.

And as we discussed, vaccine hesitancy driven by misinformation is a growing problem, even in wealthy countries.

Okay, let's shift gears.

We've talked about preventing disease with immunology.

How does it help us diagnose it?

A whole other side of the coin.

Understanding immune reactions lets us develop powerful diagnostic tests.

Two key ideas here are sensitivity and specificity.

Sensitivity?

Mm -hmm.

That's correctly identifying people with the disease.

A true positive.

Exactly.

And specificity is correctly identifying people without the disease.

A true negative.

You ideally want tests that are high in both.

And this idea is new either.

Not at all.

Think back to Robert Koch and tuberculosis.

He noticed infected guinea pigs had a skin reaction to TB extracts.

That became the tuberculin skin test, a diagnostic based on an immune response discovered even before we really understood antibodies.

So the basic idea is using immune components to find their counterparts.

Pretty much.

You can use a known antibody to detect an unknown antigen, like part of a microbe, or use a known antigen to detect unknown antibodies in a patient's blood, maybe to see if they're immune or have been infected.

But antibodies are tiny.

You can't see them.

That's the challenge.

You need indirect methods to reveal their presence or their reaction.

Which brings us to monoclonal antibodies.

MABs.

Ah, MABs.

A truly revolutionary tool.

They're produced using this amazing technique involving hybridomas.

Hybridomas.

You fuse an antibody -producing B cell from an animal immunized with the antigen you want, with a cancerous B cell, a myeloma cell that can live forever in culture.

So you get a hybrid cell that makes one specific antibody and divides endlessly.

A factory producing huge amounts of a single, identical, highly specific antibody.

Monoclonal meaning from a single clone of cells.

In the benefit.

Uniformity, high specificity, and basically unlimited supply.

They become essential for diagnostic kits, pregnancy tests, tests for infectious diseases, drug tests.

And also therapies, right?

Hugely important therapeutically.

Over 60 MABs are approved drugs now.

Treating multiple sclerosis, Crohn's, psoriasis, arthritis, many cancers.

It's a massive field.

And they've been refined over time to be more human.

Yes, because the first MABs were made using mouse cells, some patients had immune reactions to them.

So scientists developed chimeric MABs, part mouse, part human, then humanized MABs, mostly human, and now fully human MABs, made using transgenic mice or phage display technology.

You often see the naming convention O -MAB for mouse, Dizzy -MAB for chimeric, Zoomab for humanized, Umab for fully human.

Okay, so MABs are a key tool.

Let's get into some of the actual diagnostic techniques that use antibodies or detect immune reactions.

Right.

First, maybe the simplest conceptually, precipitation reactions.

This is when soluble antigens and soluble antibodies bind together and form visible clumps, a precipitate that falls out of solution.

Like mixing two liquids and getting solids.

Kinda, yeah.

It only works well when you have the right ratio of antigen to antibody that's the zone of equivalence, too much of one or the other, and you don't see the precipitate form properly.

There are tests like the precipitin ring test or immunodiffusion tests based on this.

Okay.

What about agglutination reactions?

Similar idea, but here the antigens are particulate.

They're either whole cells, like bacteria or red blood cells, or they're soluble antigens attached to particles, like latex beads.

When antibodies bind, they cause these particles to visibly clump together agglutinate.

More sensitive than precipitation.

Generally, yes, and often easier to see.

Direct agglutination detects antibodies against these large cellular antigens.

We use it to measure antibody levels, or titer, in serum.

A rising titer can indicate an active infection that's called seroconversion.

And indirect agglutination.

Indirect or passive agglutination is where you take a soluble antigen and stick it onto a particle, like a latex bead.

Then you add the patient's serum.

If antibodies are present, the beads clump.

Very common for rapid tests, like strep throat tests in the doctor's office.

Hemagglutination just involves red blood cells.

Right.

Specific type of agglutination using red blood cells, used for blood typing, for example.

Okay.

What about neutralization reactions?

Here,

antibodies block the harmful effects of something.

For instance, antitoxins are antibodies that neutralize bacterial toxins, or antibodies can prevent viruses from infecting cells.

How do you test for that?

One way is the viral hemagglutination inhibition test.

Some viruses naturally make red blood cells clump.

That's viral hemagglutination.

If you add serum containing antibodies against that virus, the antibodies bind the virus and prevent it from clumping the red blood cells.

So no clumping means antibodies are present.

Clever.

Are there others?

Complement fixation reactions.

These are a bit more complex.

They detect small amounts of antibody by seeing if complement proteins part of the immune system get used up or fixed when antigen and antibody bind.

Used to be common, like for syphilis, but mostly replaced now.

More modern techniques.

Definitely.

Fluorescent antibody FA techniques are widely used.

You attach a fluorescent dye to an antibody.

When the antibody binds its target and you shine UV light on it, it glows.

Very specific and quick.

Very.

Direct FA uses labeled antibodies to find microbes directly in patient samples, like the rabies test.

Indirect FA is often more sensitive.

You use it to detect antibodies in the patient's serum.

For example, add patient serum to cells containing the suspected antigen, then add a fluorescent anti -human antibody.

If the patient had antibodies, they'll bind, and the fluorescent antibody will then bind to them, making the cells glow.

And FACS.

Fluorescence -activated cell sorter.

It's a machine that uses FA labeling to rapidly count and even physically sort different types of cells based on the markers they have.

Crucial for monitoring immune cells, like CD4 T cells in HIV AIDS.

And probably the most common test now, ELISA.

Yes, ELISA, enzyme -linked immunosorbent assay, or sometimes EIA.

Hugely popular, often automated, easy to read results.

There's direct ELISA, which detects antigens like testing urine for drugs.

And indirect.

Indirect ELISA detects antibodies.

This is the standard for screening blood donations for HIV antibodies, for example.

Home pregnancy tests are also a form of ELISA, detecting the hormone HCG.

The enzyme -linked part means the final detection step involves an enzyme reaction that produces a color change.

And one more, Western blotting.

Right, Western blotting or immunoblotting.

This is often used as a confirmatory test, like for HIV or Lyme disease.

After an initial screening test, like ELISA is positive, it's more specific.

You separate proteins from the microbe by size, using electrophoresis, transfer them to a membrane, and then use enzyme -linked antibodies to identify if a specific target protein is present.

It really shows how layered these diagnostic strategies can be.

So looking ahead again, what's next for diagnostic immunology?

Well, MABs in these nucleic acid tests, the NADATs, are driving development of even better tests, more sensitive, more specific, faster, simpler.

They're replacing older, slower methods like culturing for things like chlamydia, or difficult microscopic diagnosis for some parasites.

More automation too.

Definitely.

Things like DNA chips or microarrays can test for thousands of targets at once.

But a huge ongoing need is for really inexpensive, simple, robust tests for major diseases in low -resource settings – malaria, TB, AIDS, neglected tropical diseases.

That remains a critical challenge.

It feels like the field is also moving beyond just finding disease to actively preventing it through rapid detection, like in food safety you mentioned earlier.

Absolutely.

And the therapeutic side, especially with MABs, is just exploding, targeting inflammation, cancer, it's transforming treatment.

So we've covered a lot of ground.

From harnessing the immune system with vaccines that protect whole populations to using its intricate reactions for incredibly precise diagnosis, it's just a constantly evolving field, isn't it?

Driven by this deeper and deeper understanding of our own defenses.

It truly is.

And maybe a final thought for you, our listener.

Considering everything, new pathogens emerging, microbes adapting, what do you think is the next big frontier?

How else can we leverage our immune system for global health?

What's the next challenge or breakthrough?

A great question to ponder.

Thank you so much for joining us on this deep dive into the practical applications of immunology.

We really hope you feel more informed, maybe a bit inspired, and definitely more curious about this invisible world inside and around us and our amazing immune response to it all.